Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
MHC class I antigen-processing machinery<br />
60f.<br />
MHC class I antigen-processing pathway 30ff.<br />
MHC class I down regulation 69±76<br />
MHC class I expression, effects of IL-10 166<br />
MHC class I loss 66±69, 72±76<br />
MHC class I molecules 43<br />
MHC class I-restricted CD8 + T cells 234<br />
MHC class II antigen-processing machinery<br />
61f., 79ff.<br />
MHC class II-associated Ii peptide (CLIP) 62<br />
MHC class II expression<br />
±, antitumor response 82f.<br />
±, modulation of immune response 81f.<br />
MHC class II-restricted T cell epitopes 232<br />
MHC class II transactivator (CIITA) 81±84<br />
MHC haplotypes 215, 222<br />
MHC locus 59<br />
microenvironment 47<br />
±, tumor 311, 327<br />
MIF see macrophage migration inhibitory<br />
factor<br />
migration, dendritic cells 180f.<br />
MIIC, MHC class II compartment 62<br />
mimicry, molecular 211, 222, 224<br />
mimotopes 44<br />
mitogen-activated protein kinases (MAPKs)<br />
270ff.<br />
mixed lymphocyte tumor cell culture (MLTC)<br />
41f.<br />
MLTC see mixed lymphocyte tumor cell<br />
culture<br />
MMPs see matrix metalloproteinases<br />
Mo-DCs 184±193<br />
mobilization, DC 183<br />
models<br />
±, animal 230<br />
±, of tumors 218±221<br />
±, T-body approach 292f.<br />
modulation of the expression of HSPs 261f.<br />
modulation of the site of HSP expression<br />
262f.<br />
molecular mimicry 211, 222<br />
±, definition 224<br />
monitoring<br />
±, CTL responses 44±49<br />
±, immunoresponses 194f.<br />
monoclonal antibodies (mAbs) 17f.<br />
±, bacterial immunotherapy 277<br />
±, discovery 311<br />
±, immunotoxin therapy 360f.<br />
±, immunotoxins 363±366<br />
monocytes<br />
±, effects of IL-10 126, 158f.<br />
±, effects of polyamines 133f.<br />
±, effects of prostagl<strong>and</strong>in (PG) E2 131<br />
±, effects of TGF-b 121<br />
±, plasmacytoid 179f.<br />
morphology, plasmacytoid 179<br />
moxibustion, HSPs 261<br />
mRNA, HCV 240<br />
MUC1, HCV 238f.<br />
mucins, tumor-shed antigens 134f.<br />
multiple myeloma<br />
±, clinical trials 189, 193<br />
multiple peptide epitopes 187<br />
mutated antigens 21f., 231<br />
mutations, oncogenic 206ff.<br />
myeloid APCs, effects of IL-10 158f.<br />
myeloid DCs 179<br />
myeloid-derived DCs 105<br />
Index<br />
n<br />
natural killer (NK) cells 63, 65f., 218<br />
±, bacterial immunotherapy 273ff.<br />
±, effects of dendritic cells 181, 195<br />
±, effects of IL-10 128, 160, 166<br />
±, effects of polyamines 134<br />
±, effects of prostagl<strong>and</strong>in (PG) E2 132<br />
±, effects of TGF-b 123<br />
±, HLA-G expression 88<br />
±, immunocytokines 328f., 338f.<br />
±, inhibition <strong>by</strong> MIF 130<br />
±, tumor microenvironment 101±104<br />
NDF see Neuregulin differentiation factor<br />
near-self antigens, definition 224<br />
near-self epitopes 209, 211<br />
nerve growth factor, low-affinity receptor<br />
304f.<br />
Neuregulin differentiation factor (NDF) 292<br />
neuroblastoma, immunocytokines 337±342<br />
neutrophils, FasL 112<br />
NF-kB, T cells 100<br />
NHL see non-Hodgkin lymphomas<br />
nitric oxide (NO)<br />
±, effects of IL-10 165<br />
±, immune response inhibitor 81<br />
NK see natural killer<br />
NK inhibitory receptor see killer inhibitory<br />
receptors<br />
NO see nitric oxide<br />
non-Hodgkin lymphomas (NHL)<br />
±, clinical trials 189<br />
±, effects of IL-10 163<br />
non-individualized tumor vaccine 332<br />
NSX2 cells<br />
±, neuroblastoma 337f., 340<br />
nuclease activity 272<br />
403
Change language